secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001785530-24-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports Q4 2023 net loss $12M; CSO retiring March 29, 2024
--------------------------------------------------------------------------------

- Net loss of $12.0M in Q4 2023 ($37.4M full year) vs $11.9M in Q4 2022.
- Cash and equivalents $134.3M plus restricted cash $21.2M as of Dec 31, 2023.
- Cash runway extended through Q2 2025, including $17.7M ATM proceeds in early 2024.
- Collaboration revenue from Jazz fell to $1.5M Q4 from $7.3M year ago.
- CSO Cynthia Seidel-Dugan retiring effective March 29, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/0001785530-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/howl-20240307.htm
  HTML page:      https://secwatch.observer/filing/0001785530-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer